Insider · SEC Form 4 filer

Jeremy Green

Past buys: 0 of 3 beat

Companies

Where they file as an insider

Attovia Therapeutics (ATTO) 10% owner Latest filing Aug 6, 2026

Fate Therapeutics (FATE) Director, 10% owner Latest filing Apr 20, 2026

IGM Biosciences (IGMS) 10% owner Latest filing Aug 14, 2025

ADC Therapeutics SA (ADCT) 10% owner Latest filing Dec 11, 2024

Shattuck Labs (STTK) Director, 10% owner Latest filing Dec 4, 2024

Augmedix (AUGX) Director, 10% owner Latest filing Oct 2, 2024

Science 37 (SNCE) Insider Latest filing Mar 12, 2024

Absci (ABSI) Director Latest filing Mar 1, 2024

Track record

Did their buys beat the typical stock?

Open-market buys3

Quarters checked 6 months later3

Beat the typical stock 0 of 3

Quarters too new to check0

0 of 3 checked quarters beat the typical stock. A past record is data, not a forecast.

Fate Therapeutics (FATE) Bought Dec 20, 2024 · $669K · 397,964 shares Behind typical Dec 31, 2024 $1.65 → Jun 30, 2025 $1.12 · −32.1% (typical stock −3.4%)

Shattuck Labs (STTK) Bought Dec 4, 2024 · $167K · 133,371 shares Behind typical Dec 31, 2024 $1.21 → Jun 30, 2025 $0.79 · −34.6% (typical stock −3.4%)

Absci (ABSI) Bought Mar 1, 2024 · $1000K · 222,222 shares Behind typical Mar 31, 2024 $5.68 → Sep 30, 2024 $3.82 · −32.7% (typical stock +3.2%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Jeremy Green

Where they file as an insider

Did their buys beat the typical stock?

Free weekly email